Dec 19 (Reuters) - BioMarin Pharmaceutical (BMRN) said on Friday it would acquire Amicus Therapeutics (FOLD) for about $4.8 billion, expanding its presence in rare metabolic diseases.
The drugmaker will pay $14.50 per share for Amicus, a premium of 33.1% to the stock's last close. Shares of Amicus surged 30%, while BioMarin rose nearly 5% in premarket trading.
The deal strengthens BioMarin's portfolio with Amicus' approved genetic disorder treatments including Galafold, an oral drug for Fabry disease, which is caused by a faulty gene that leads to a buildup of fatty substances in cells.
Amicus also markets a combination therapy Pombiliti and Opfolda for Pompe disease, a genetic condition in which a complex sugar called glycogen builds up in the body's cells.
Amicus also has U.S. rights to DMX-200, a potential treatment of a type of kidney disease known as focal segmental glomerulosclerosis.
BioMarin intends to finance the deal through a combination of cash on hand and about $3.7 billion of non-convertible debt financing.
The company's total cash and investments at the end of September 30 were about $2 billion.
The acquisition, which is expected to close in the second quarter of 2026, will add revenue immediately after the transaction closes, BioMarin said.
The deal is also expected to add to adjusted profit in the first 12 months after close and be substantially accretive beginning in 2027, the company said.
(Reporting by Christy Santhosh and Sriparna Roy in Bengaluru; Editing by Leroy Leo and Maju Samuel)
LATEST POSTS
- 1
The 20 Most sultry Style of the Time - 2Satellite constellations could obscure most space telescope observations by late 2030s: 'That part of the image will be forever lost'
- 3Chemical leak in Oklahoma forces evacuations and leaves many ill
- 4Five EU states press for windfall taxes on fossil energy sector
- 5Authorities arrest 7 bodyguards in connection with a Mexican mayor's assassination
- Impact of NIH funding reductions felt in cancer and infectious disease trials
- Study casts doubt on potential for life on Jupiter's moon Europa
- Winter storms blanket the East, while the U.S. West is wondering: Where’s the snow?
- Remarkable Spots for Hot Air Swelling All over The Planet
- Explainer-What has happened to the damaged spacecraft at China's space station?
- 'No middle ground' for tackling antisemitism after Bondi Beach mass shooting, deputy FM Haskel says
- Churches and politicians in South Sudan call for 'lasting peace' in Easter messages
- Kendall Jenner addresses long-standing rumor about her sexuality
- The Solution to Individual budget: Dominating Cash The board
